In some cases, the problem may be that
industry is taking over more study designs and
doing so with marketing in mind. “It’s about
‘How can we broaden out the uses of this drug,
how can we promote it among more populations’…
studies are marketing designs rather
than public health designs. It doesn’t advance
the body of evidence-based medicine in this
country,” says
Jennifer Washburn, author of
University, Inc.: The Corporate Corruption
of Higher Education and a fellow at the
New
America Foundation in Washington, DC.
Original article (subscription required)
See all New America articles, appearances & citations from Nature Biotechnology
